 NEW YORK and CLEVELAND, Dec. 21, 2020 GLOBE NEWSWIRE -- Abeona Therapeutics Inc. Nasdaq: ABEO, a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interim results from its ABO-102 Phase 12 Transpher A study for MPS IIIA and ABO-101 Phase 12 Transpher B study for MPS IIIB have been accepted for platform oral presentations during the late-breaking abstract session at the 17th Annual WORLDSymposiumTM being held February 8-12, 2021. 